Hospira extends acquisition offer to Javelin
LAKE FOREST, Ill. Hospira has extended its $145 million offer to buy Javelin Pharmaceuticals, the generic drug maker said Wednesday.
The offer, originally made in April, was set to expire at the end of Tuesday, but will now expire at the end of June 2.
Hospira said Javelin had not satisfied all the conditions for acquisition, which Javelin said was due to a supply-chain problem with the painkiller Dyloject in the United Kingdom, though Javelin expressed disagreement with Hospira’s position.